A biotechnology patent application should connect biological structure, function, experimental evidence and practical utility. Strong drafting defines what was actually invented, supports the intended genus or species scope, records sequence and assay details where material, and preserves fallback positions for later US, EPO and international prosecution.
Biotechnology inventions may involve proteins, antibodies, nucleic acids, vectors, engineered cells, microorganisms, diagnostics, assays, biomarkers, gene editing, biologics and manufacturing processes. The drafting challenge is to claim the commercial invention without extending beyond what the application actually teaches, while preserving enough structural and functional detail for later amendment and prosecution.
Identify what is new at the biological level: a sequence, engineered construct, binding relationship, functional property, process, composition, assay architecture, therapeutic use or technical combination. A broad goal such as “treat disease X” is not a substitute for describing the biological invention that achieves it.
Life-science value often depends on coverage broader than one tested molecule. The specification should therefore explain which structural and functional features define the invention, why alternatives are expected to work, and what representative embodiments support the broader scope.
Biotechnology sits in a comparatively unpredictable technical field. Small changes in sequence, structure, expression system, formulation or assay conditions can materially change biological behaviour. That makes disclosure strategy especially important: broad claims may need representative examples, structural definitions, sequence information, functional assays or a credible structure-function relationship to support the desired scope.
For US practice, the USPTO treats written description and enablement as distinct requirements under 35 U.S.C. §112(a). Its current MPEP explains that possession of a biotechnology genus can be shown through representative species, identifying structural characteristics, or functional characteristics coupled with a known or disclosed structure-function correlation. USPTO MPEP §2163.
Drafting should separate characteristics that are essential to biological activity from characteristics that are merely optional implementation choices. Depending on the invention, the relevant identifiers may include nucleotide or amino-acid sequence, CDR sequence, domain architecture, epitope, binding affinity, expression phenotype, catalytic activity, cellular response, biomarker relationship, mutation profile or manufacturing property.
| Biotechnology subject | Useful drafting anchors | Risk if omitted |
|---|---|---|
| Antibodies | CDRs, variable regions, antigen/epitope, affinity, functional properties, formats | Function-only claims may exceed disclosed structural scope |
| Nucleic acids / proteins | Sequences, variants, identity thresholds, conserved residues, function | Broad sequence genus may lack support or enablement |
| Engineered cells | Constructs, host type, expression components, phenotype, assay evidence | Claim may read as a desired result without implementation support |
| Diagnostics | Marker, threshold, assay method, sample type, technical relationship | Correlation may be described without a reproducible technical method |
| Manufacturing | Process parameters, host conditions, purification steps, product attributes | Commercially important process space may not be captured |
A common biotechnology drafting issue is whether a limited set of examples can support a broader genus. The USPTO states that, where a genus contains substantial variation, the disclosure should contain a representative number of species or identifying characteristics that show possession of the breadth claimed. One species will not automatically support a broad unpredictable genus. The draft should therefore map the intended claim breadth against the structural diversity actually disclosed.
The specification should enable the skilled person to make and use the claimed invention without undue experimentation across the scope that matters. For biotechnology inventions, this may require protocols, assay methods, construct details, sequence definitions, experimental conditions, representative examples and explanations of which variables can change without losing the technical effect.
The drafting objective is not to add experimental volume for its own sake. It is to ensure that the specification teaches enough for the intended scope, including the parts of the scope most likely to be challenged later.
International applications filed on or after 1 July 2022 that disclose qualifying nucleotide or amino-acid sequences use the XML-based WIPO Standard ST.26. The EPO's current PCT guidance confirms that qualifying sequence disclosures must use an ST.26-compliant sequence listing and recommends WIPO Sequence for preparing the listing. EPO PCT Guidelines A-IV, 3.
The drafting team should coordinate the narrative description, sequence identifiers and XML listing from the beginning. Sequence identifiers used in the description should map consistently to the listing, and fragments or variants intended as claim fallbacks should be disclosed deliberately rather than added only after examination raises an issue.
For antibody inventions, a specification should normally disclose the antibody's structural identity alongside any functional properties relied on for scope. The EPO's April 2026 Guidelines state that an IgG defined structurally normally needs the sequences of the CDRs required for antigen binding, and that functional definition by target antigen is possible only where the antigen is clearly defined. EPO Guidelines G-II, 6.1.1 and G-II, 6.1.2.
This makes a layered disclosure valuable: sequence definitions, CDR numbering scheme where relevant, antigen or epitope definition, binding data, affinity ranges, neutralisation or other functional properties, antibody formats and alternative sequence variants.
The EPO's 2026 antibody guidance states that a novel antibody to a known antigen is not automatically inventive merely because its sequence differs. Inventive step may depend on a surprising technical effect, an unexpected property, absence of a reasonable expectation of success, or technical difficulty in generating or manufacturing the antibody. EPO Guidelines G-II, 6.2.
Where such effects matter commercially, the original filing should describe them clearly and include the evidence then available. Later prosecution is easier when the specification already records the comparative performance, stability, specificity, manufacturability or biological effect relied upon.
Sequence-based claims can be drafted at several levels: exact sequences, defined variants, identity thresholds, conserved residues, functional limitations, encoded products, expression constructs and use claims. The specification should explain why the broader variants are expected to retain the relevant activity, rather than relying on a percentage-identity number with no biological rationale.
For the EPO, the industrial application of a gene sequence or partial sequence must be disclosed in the application as filed. The current 2026 Guidelines also confirm that isolated biological material can in principle be patentable, subject to the EPC biotechnology provisions. EPO Guidelines G-II, 5.2.
Examples should show enough of the inventive landscape to support useful fallback positions. Consider including different species, concentrations, constructs, hosts, assay conditions, sequence variants, formulations or process conditions where they illuminate the scope. Negative or comparative data can also help explain why the invention works and where its technical contribution lies.
The goal is to convert experimental work into patent disclosure that supports both the broad commercial concept and narrower positions that may be needed after prior-art searching.
| Claim layer | Purpose | Typical biotechnology content |
|---|---|---|
| 1. Commercial concept | Capture the central invention | Core molecule, composition, cell, assay or process |
| 2. Structural definition | Anchor possession and clarity | Sequence, CDRs, domains, construct or process steps |
| 3. Functional definition | Capture biological performance | Binding, inhibition, expression, diagnostic or therapeutic effect |
| 4. Representative variants | Preserve practical breadth | Species, substitutions, formats, ranges, host systems |
| 5. Narrow fallback | Create prosecution positions | Specific sequence, assay, dosage, process condition or combination |
The biotechnology hub should preserve an international disclosure base while the jurisdiction children handle the deeper legal rules. For the United States, particular attention should be given to written description, enablement and the relationship between representative species and genus scope. For the EPO, additional emphasis falls on structural definition, amendment basis, industrial application, exclusions and biotechnology-specific inventive-step practice.
Once live, the US and EPO biotechnology drafting pages should be linked here as dedicated children. Until then, use the broader jurisdiction guides for US patent drafting and EPO patent drafting.
Biotechnology drafting is strongest when structure, function, experimental evidence and fallback claim positions are coordinated before filing. The shared featured video provides additional context on patenting technology-driven inventions.
Discuss the biological invention, experimental support, claim architecture, target markets and desired protection outcome before filing.
